What is Pfizer's indefinite- lived intangible impairment?

Pfizer (PFE) reported indefinite- lived intangible impairment of $126.42B in Q1 2026.

How has Pfizer's indefinite- lived intangible impairment changed year-over-year?

Pfizer's indefinite- lived intangible impairment increased by 3.0% year-over-year, from $122.75B to $126.42B.

What is the long-term trend for Pfizer's indefinite- lived intangible impairment?

Over 5 years (2020 to 2025), Pfizer's indefinite- lived intangible impairment has grown at a 9.2% compound annual growth rate (CAGR), from $81.33B to $126.23B.

Pfizer PFE Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

Merck & Co.MRK

——

ViatrisVTRS

——

BiogenBIIB

——

Vertex PharmaceuticalsVRTX

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+5.0%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$143.68B+11.1%

Enterprise value$206.35B+9.2%

P/E11.9×—

P/S2.3×+0.2×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's indefinite- lived intangible impairment?: Pfizer (PFE) reported indefinite- lived intangible impairment of $126.42B in Q1 2026.
How has Pfizer's indefinite- lived intangible impairment changed year-over-year?: Pfizer's indefinite- lived intangible impairment increased by 3.0% year-over-year, from $122.75B to $126.42B.
What is the long-term trend for Pfizer's indefinite- lived intangible impairment?: Over 5 years (2020 to 2025), Pfizer's indefinite- lived intangible impairment has grown at a 9.2% compound annual growth rate (CAGR), from $81.33B to $126.23B.